Less-than-standard treatment in rectal cancer patients

Which patients are at risk?

Maria Pisu, Lisa C. Richardson, Young Il Kim, Helen Krontiras, Michelle Martin, Maribel Salas, Lori A. Pollack

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: Guidelines recommend that patients with non-metastatic rectal cancer receive surgery and adjuvant chemotherapy and/or radiation therapy (XRT) after surgery (especially if stage Il and III). Studies reported that 90% of stage Il and III patients received surgery, and 70% received adjuvant treatment. In states where socioeconomics and limited medical resources may hinder treatment, cancer care is understudied. The objective is to describe initiation and completion of rectal cancer treatment in Alabama. Methods: Medicare claims were obtained for 675 stage I to III rectal cancer patients diagnosed in 1999-2003, enrolled in fee-for-service Medicare, and with at least 9 months of follow-up. Logistic regressions were used to identify significant differences by sex, age, and race in the likelihood of initiating treatment and receiving an incomplete course of chemotherapy or XRT (≤120 days of chemotherapy and ≤28 days of XRT). Results: Overall, 90% received surgery, of which 43% received some adjuvant treatment. Among stage Il to III patients, 58.8% received adjuvant treatment. Except for patients aged 75 years and greater being less likely to start chemotherapy, there were no significant differences in initiation by age, sex, and race. Depending on concurrent administration of chemotherapy and XRT, 29% to 35% received incomplete chemotherapy, and 16% to 23% incomplete XRT. Women were more likely to have incomplete chemotherapy than men. Conclusions: Adjuvant treatment was less than reported in previous studies. Treatment initiation and completion did not differ across demographic factors. Future studies should explore reasons why older rectal cancer patients in Alabama are less likely to receive recommended treatment.

Original languageEnglish (US)
Pages (from-to)190-198
Number of pages9
JournalJournal of the National Medical Association
Volume102
Issue number3
DOIs
StatePublished - Jan 1 2010

Fingerprint

Rectal Neoplasms
Drug Therapy
Therapeutics
Medicare
Fee-for-Service Plans
Adjuvant Chemotherapy
Sex Characteristics
Radiotherapy
Logistic Models
Demography
Guidelines

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Less-than-standard treatment in rectal cancer patients : Which patients are at risk? / Pisu, Maria; Richardson, Lisa C.; Kim, Young Il; Krontiras, Helen; Martin, Michelle; Salas, Maribel; Pollack, Lori A.

In: Journal of the National Medical Association, Vol. 102, No. 3, 01.01.2010, p. 190-198.

Research output: Contribution to journalArticle

Pisu, Maria ; Richardson, Lisa C. ; Kim, Young Il ; Krontiras, Helen ; Martin, Michelle ; Salas, Maribel ; Pollack, Lori A. / Less-than-standard treatment in rectal cancer patients : Which patients are at risk?. In: Journal of the National Medical Association. 2010 ; Vol. 102, No. 3. pp. 190-198.
@article{0da8805ef4bc4351958d11a272df50a4,
title = "Less-than-standard treatment in rectal cancer patients: Which patients are at risk?",
abstract = "Objective: Guidelines recommend that patients with non-metastatic rectal cancer receive surgery and adjuvant chemotherapy and/or radiation therapy (XRT) after surgery (especially if stage Il and III). Studies reported that 90{\%} of stage Il and III patients received surgery, and 70{\%} received adjuvant treatment. In states where socioeconomics and limited medical resources may hinder treatment, cancer care is understudied. The objective is to describe initiation and completion of rectal cancer treatment in Alabama. Methods: Medicare claims were obtained for 675 stage I to III rectal cancer patients diagnosed in 1999-2003, enrolled in fee-for-service Medicare, and with at least 9 months of follow-up. Logistic regressions were used to identify significant differences by sex, age, and race in the likelihood of initiating treatment and receiving an incomplete course of chemotherapy or XRT (≤120 days of chemotherapy and ≤28 days of XRT). Results: Overall, 90{\%} received surgery, of which 43{\%} received some adjuvant treatment. Among stage Il to III patients, 58.8{\%} received adjuvant treatment. Except for patients aged 75 years and greater being less likely to start chemotherapy, there were no significant differences in initiation by age, sex, and race. Depending on concurrent administration of chemotherapy and XRT, 29{\%} to 35{\%} received incomplete chemotherapy, and 16{\%} to 23{\%} incomplete XRT. Women were more likely to have incomplete chemotherapy than men. Conclusions: Adjuvant treatment was less than reported in previous studies. Treatment initiation and completion did not differ across demographic factors. Future studies should explore reasons why older rectal cancer patients in Alabama are less likely to receive recommended treatment.",
author = "Maria Pisu and Richardson, {Lisa C.} and Kim, {Young Il} and Helen Krontiras and Michelle Martin and Maribel Salas and Pollack, {Lori A.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/S0027-9684(15)30525-3",
language = "English (US)",
volume = "102",
pages = "190--198",
journal = "Journal of the National Medical Association",
issn = "1943-4693",
publisher = "National Medical Association",
number = "3",

}

TY - JOUR

T1 - Less-than-standard treatment in rectal cancer patients

T2 - Which patients are at risk?

AU - Pisu, Maria

AU - Richardson, Lisa C.

AU - Kim, Young Il

AU - Krontiras, Helen

AU - Martin, Michelle

AU - Salas, Maribel

AU - Pollack, Lori A.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objective: Guidelines recommend that patients with non-metastatic rectal cancer receive surgery and adjuvant chemotherapy and/or radiation therapy (XRT) after surgery (especially if stage Il and III). Studies reported that 90% of stage Il and III patients received surgery, and 70% received adjuvant treatment. In states where socioeconomics and limited medical resources may hinder treatment, cancer care is understudied. The objective is to describe initiation and completion of rectal cancer treatment in Alabama. Methods: Medicare claims were obtained for 675 stage I to III rectal cancer patients diagnosed in 1999-2003, enrolled in fee-for-service Medicare, and with at least 9 months of follow-up. Logistic regressions were used to identify significant differences by sex, age, and race in the likelihood of initiating treatment and receiving an incomplete course of chemotherapy or XRT (≤120 days of chemotherapy and ≤28 days of XRT). Results: Overall, 90% received surgery, of which 43% received some adjuvant treatment. Among stage Il to III patients, 58.8% received adjuvant treatment. Except for patients aged 75 years and greater being less likely to start chemotherapy, there were no significant differences in initiation by age, sex, and race. Depending on concurrent administration of chemotherapy and XRT, 29% to 35% received incomplete chemotherapy, and 16% to 23% incomplete XRT. Women were more likely to have incomplete chemotherapy than men. Conclusions: Adjuvant treatment was less than reported in previous studies. Treatment initiation and completion did not differ across demographic factors. Future studies should explore reasons why older rectal cancer patients in Alabama are less likely to receive recommended treatment.

AB - Objective: Guidelines recommend that patients with non-metastatic rectal cancer receive surgery and adjuvant chemotherapy and/or radiation therapy (XRT) after surgery (especially if stage Il and III). Studies reported that 90% of stage Il and III patients received surgery, and 70% received adjuvant treatment. In states where socioeconomics and limited medical resources may hinder treatment, cancer care is understudied. The objective is to describe initiation and completion of rectal cancer treatment in Alabama. Methods: Medicare claims were obtained for 675 stage I to III rectal cancer patients diagnosed in 1999-2003, enrolled in fee-for-service Medicare, and with at least 9 months of follow-up. Logistic regressions were used to identify significant differences by sex, age, and race in the likelihood of initiating treatment and receiving an incomplete course of chemotherapy or XRT (≤120 days of chemotherapy and ≤28 days of XRT). Results: Overall, 90% received surgery, of which 43% received some adjuvant treatment. Among stage Il to III patients, 58.8% received adjuvant treatment. Except for patients aged 75 years and greater being less likely to start chemotherapy, there were no significant differences in initiation by age, sex, and race. Depending on concurrent administration of chemotherapy and XRT, 29% to 35% received incomplete chemotherapy, and 16% to 23% incomplete XRT. Women were more likely to have incomplete chemotherapy than men. Conclusions: Adjuvant treatment was less than reported in previous studies. Treatment initiation and completion did not differ across demographic factors. Future studies should explore reasons why older rectal cancer patients in Alabama are less likely to receive recommended treatment.

UR - http://www.scopus.com/inward/record.url?scp=77950624436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950624436&partnerID=8YFLogxK

U2 - 10.1016/S0027-9684(15)30525-3

DO - 10.1016/S0027-9684(15)30525-3

M3 - Article

VL - 102

SP - 190

EP - 198

JO - Journal of the National Medical Association

JF - Journal of the National Medical Association

SN - 1943-4693

IS - 3

ER -